Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Unknown 2Recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 25Stomach Neoplasms 9Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Hodgkin Disease 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Uveal Melanoma 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Carcinoma 2Brain Neoplasms 2

Interventions

Cyclophosphamide 16fludarabine 12Rituximab 4Antigens, CD19 4Lenalidomide 3Immunotherapy, Adoptive 3Etoposide 3orelabrutinib 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Methotrexate 2zanubrutinib 1relmacabtagene autoleucel 1prednylidene 1obinutuzumab 1merphos 1ixazomib 1gemcitabine-oxaliplatin regimen 1fludarabine phosphate 1entecavir 1eltrombopag 1deltacortene 1abivertinib 1Vincristine 1Transplantation, Autologous 1Tenofovir 1Prednisone 1Pentostatin 1Melphalan 1Interleukin-7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lymphoma, B-Cell × Nivolumab × Clear all
NCT05385263 2022-05-26

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Tel-Aviv Sourasky Medical Center

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, B-Cell

NCT03569696 2019-04-23

NivoM

Sheba Medical Center

Phase 2 Unknown
50 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡